chrX-38401372-G-C
Variant summary
Our verdict is Pathogenic. The variant received 17 ACMG points: 17P and 0B. PS1PM1PM2PM5PP2PP3_StrongPP5_Moderate
The NM_000531.6(OTC):c.484G>C(p.Gly162Arg) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 12/21 in silico tools predict a damaging outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★). Another nucleotide change resulting in the same amino acid substitution has been previously reported as Pathogenic in ClinVar. Another variant affecting the same amino acid position, but resulting in a different missense (i.e. G162A) has been classified as Likely pathogenic.
Frequency
Consequence
NM_000531.6 missense
Scores
Clinical Significance
Conservation
Publications
- ornithine carbamoyltransferase deficiencyInheritance: XL Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Labcorp Genetics (formerly Invitae), ClinGen, G2P, Laboratory for Molecular Medicine, Orphanet
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 17 ACMG points.
Variant Effect in Transcripts
ACMG analysis was done for transcript: NM_000531.6. You can select a different transcript below to see updated ACMG assignments.
RefSeq Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| OTC | NM_000531.6 | MANE Select | c.484G>C | p.Gly162Arg | missense | Exon 5 of 10 | NP_000522.3 | ||
| OTC | NM_001407092.1 | c.484G>C | p.Gly162Arg | missense | Exon 7 of 12 | NP_001394021.1 |
Ensembl Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| OTC | ENST00000039007.5 | TSL:1 MANE Select | c.484G>C | p.Gly162Arg | missense | Exon 5 of 10 | ENSP00000039007.4 | ||
| ENSG00000250349 | ENST00000465127.1 | TSL:5 | c.172-264749G>C | intron | N/A | ENSP00000417050.1 | |||
| OTC | ENST00000713758.1 | c.484G>C | p.Gly162Arg | missense | Exon 7 of 12 | ENSP00000519059.1 |
Frequencies
GnomAD3 genomes Cov.: 23
GnomAD4 exome Cov.: 28
GnomAD4 genome Cov.: 23
ClinVar
Submissions by phenotype
Ornithine carbamoyltransferase deficiency Pathogenic:1
For these reasons, this variant has been classified as Pathogenic. This variant disrupts the p.Gly162 amino acid residue in OTC. Other variant(s) that disrupt this residue have been observed in individuals with OTC-related conditions (PMID: 16786505), which suggests that this may be a clinically significant amino acid residue. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt OTC protein function. ClinVar contains an entry for this variant (Variation ID: 97217). This missense change has been observed in individual(s) with ornithine transcarbamylase deficiency (PMID: 1353535, 16786505). In at least one individual the variant was observed to be de novo. This variant is not present in population databases (ExAC no frequency). This sequence change replaces glycine with arginine at codon 162 of the OTC protein (p.Gly162Arg). The glycine residue is highly conserved and there is a moderate physicochemical difference between glycine and arginine.
not provided Pathogenic:1
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at